Amarin (AMRN) up 4.1% premarket after posting a per-share GAAP loss of $0.18 (a $0.26 loss excluding compensation and derivative-value issues), roughly in line with analyst expectations of a $0.22-$0.25 loss. The late-stage biopharma noted an FDA approval for a use of its Vascepa capsules in treating hypertriglyceridemia, and the development of eight new patents to go alone with 30 other applications pending.
Are you Bullish or Bearish on ?
Sentiment on ()
Thanks for sharing your thoughts.